Download Sample
For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-tumor-necrosis-factor-inhibitors-drug-market-dosage-price-and-clinical-pipeline-outlook-2024.php
Table of Contents
1. Tumor Necrosis Factor : An Overview
1.1 Prologue to Tumor Necrosis Factor
1.2 History and Discovery of Tumor Necrosis Factors
2. Significance of Tumor Necrosis Factor
2.1 TNF in Cell Signaling and Immunity
2.1.1 Tumor Necrosis Factor Receptor 1
2.1.2 Tumor Necrosis Factor Receptor 2
2.2 Role of TNF in Cancer
2.3 Disease Related to TNF and Members of Its Family
3. Working Mechanism of Tumor Necrosis Factors (TNF) Inhibitors and Their Therapeutic Evolution
3.1 Tumor Necrosis Factor and Immune Response
3.2 Tumor Necrosis Factor Inhibition by Monoclonal Antibodies
4. Approaches Used in Development of TNF Inhibitors
4.1 Monoclonal Antibody Approach
4.2 Recombinant DNA Technology Approach
5. Global Tumor Necrosis Factor Alpha Inhibitors Pipeline Overview
6. Global Tumor Necrosis Factor Alpha Inhibitors Clinical Pipeline by Company, Indication and Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered
7. Marketed Global Tumor Necrosis Factor Alpha Inhibitors Clinical Insight by Company and Indication
7.1 Golimumab (Shinponi, Simponi, Simponi Aria, Simponi I.V, Sympony and Symposony)
7.2 Pomalidomide (Imnovid and Pomalyst)
7.3 Adalimumab (Humira and Raheara)
7.4 Infliximab (Remicade)
7.5 Certolizumab Pegol (CIMZIA AutoClicks Prefilled Pen, Cimzia and Simziya)
7.6 Apremilast (Otezla)
7.7 Infliximab Biosimilar – Celltrion
7.8 Lumbricus Rubellus Extract (Inflectra and Remsima)
7.9 Adalimumab Biosimilar (AdaliRel and Adfrar)
7.10 Infliximab Biosimilar (Infimab)
7.11 Infliximab Biosimilar – Bionovis/ The Instituto Vital Brazil
7.12 Adalimumab Biosimilar (Exemptia)
7.13 Anti-Tumour Necrosis Factor-Alpha Antibody Oral
8. Price, Dosage and Treatment Cost Analysis of Commercially Available TNF Based Therapeutics
8.1 Cimzia (Certolizumab Pegol)
8.2 Enbrel (Etanercept)
8.2.1 Benepali andndash; Etanercept Biosimilar
8.3 Humira ( Adalimumab)
8.3.1 Amjevita andndash; Humira Biosimilar
8.3.2 Cyltezo andndash; Second Biosimilar to Humira
8.4 Otezla (Apremilast)
8.5 Remicade (Infliximab)
8.5.1 Remsima – Infliximab Biosimilar
8.5.2 Inflectra andndash; Infliximab Biosimilar
8.6 Simponi (Golimumab)
9. Current Market Trends and Recent Advances in the TNF Inhibitors Segment
9.1 Dominance of TNF Inhibitors in Global Therapeutics Market
9.2 Global TNF Inhibitor Market by Indication andndash; Market Size and Growing Opportunity
9.2.1 Rheumatoid Arthritis
9.2.2 Psoriasis and psoriatic arthritis (PsA)
9.2.3 Crohn’s Disease
9.2.4 Ankylosing Spondylitis
9.3 Global TNF Inhibitors Market by Region
9.3.1 US
9.3.2 Europe
9.3.3 Asia- Pacific
9.3.4 Middle East and Africa (MEA)
10. TNF Inhibitor- Sales and Patent Analysis
10.1 TNF Inhibitor Market by Sales
10.1.1 Cimzia
10.1.2 Enbrel
10.1.3 Humira
10.1.4 Remicade
10.2 TNF Inhibitor Market by Approvals and Patent
10.3 TNF Inhibitor Biosimilar Sales Analysis
11. TNF Inhibitors Market Driving Parameters
12. Restraining Factors of the Global TNF Inhibitors Market
13. Global TNF Inhibitors Future Forecast and Sales Projections
13.1 Impact of Biosimilar ‘Benepali’ on Enbrel Sales
13.2 Affordable Alternatives to Humira and Their Effect on Global Humira Sales
13.3 Remicade and Its Biosimilar
13.4 Conclusion and Executive Summary
14. Competitive Landscape
14.1 AbbVie
14.2 Ablynx
14.3 Apogenix
14.4 AryoGen Biopharma
14.5 Bionovis
14.6 CASI Pharmaceuticals
14.7 Celltrion
14.8 Celgene Corporation
14.9 Delenex Therapeutics
14.10 Dexa Medica
14.11 EPIRUS Biopharmaceuticals
14.12 Janssen Biotech
14.13 GlaxoSmithKline
14.14 HanAll Biopharma
14.15 Intas Pharmaceuticals
14.16 LEO Pharma
14.17 LG Life Sciences
14.18 MedImmune
14.19 Momenta Pharmaceuticals
14.20 Novartis
14.21 PROBIOMED
14.22 Reliance Life Sciences
14.23 Sandoz
14.24 Samsung Bioepis
14.25 Sanofi-Aventis
14.26 Shanghai CP Guojian Pharmaceutical
14.27 Shanghai Pharmaceuticals
14.28 Simcere Pharmaceutical
14.29 Toyama Chemical
14.30 Tsumura
14.31 UCB
14.32 Zydus Cadila